Gilead Sciences (NASDAQ:GILD): Closing price $45.02
Gilead announced detailed Tuesday its 24-week results from a Phase 2 study (Study 102) of a once-daily single tablet regimen containing tenofovir alafenamide (TAF) for the treatment of HIV-1 infection. A regimen of TAF 10 mg/elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg was found to be similar to Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) based on the percentage of patients with HIV RNA levels less than 50 copies/mL at 24 weeks of treatment. These findings were presented in a latebreaker session (Abstract #99LB) at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.
Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.